Literature DB >> 5683536

A study of hematological complications occurring in patients with polycythemia vera treated with 32-P (based on a series of 296 patients).

M Tubiana, R Flamant, E Attie, M Hayat.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1968        PMID: 5683536

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  10 in total

1.  Present status of 32P-therapy in management of polycythemia vera.

Authors:  G Meuret
Journal:  Klin Wochenschr       Date:  1975-06-15

2.  [A contribution to the cytostatic long-term chemotherapy of polycythemia vera (author's transl)].

Authors:  W Fereberger; F P Robier; S Sailer
Journal:  Blut       Date:  1979-12

3.  32P-therapy in polycythemia vera.

Authors:  G Meuret; G Hoffmann; R Gmelin
Journal:  Klin Wochenschr       Date:  1975-06-01

4.  Treatment of polycythemia vera.

Authors:  B K MacDougall; B H Weinerman; S Kemel
Journal:  Can Med Assoc J       Date:  1979-09-08       Impact factor: 8.262

5.  Polycythemia vera. A clinical study of 141 patients.

Authors:  B Anger; U Haug; R Seidler; H Heimpel
Journal:  Blut       Date:  1989-12

Review 6.  Radionuclide therapy revisited.

Authors:  C A Hoefnagel
Journal:  Eur J Nucl Med       Date:  1991

7.  Phenotypic variability within the JAK2 V617F-positive MPD: roles of progenitor cell and neutrophil allele burdens.

Authors:  Alison R Moliterno; Donna M Williams; Ophelia Rogers; Mary Ann Isaacs; Jerry L Spivak
Journal:  Exp Hematol       Date:  2008-08-23       Impact factor: 3.084

8.  Chronic myeloproliferative disorders: prognostic importance of new working classification.

Authors:  R Burkhardt; K Jaeger; G Kettner; G Helmer
Journal:  J Clin Pathol       Date:  1990-05       Impact factor: 3.411

9.  Use and risks of phosphorus-32 in the treatment of polycythaemia vera.

Authors:  Claude Parmentier
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-09-03       Impact factor: 9.236

10.  Treatment of polycythaemia vera by radiophosphorus or busulphan: a randomized trial. "Leukemia and Hematosarcoma" Cooperative Group, European Organization for Research on Treatment of Cancer (E.O.R.T.C.).

Authors: 
Journal:  Br J Cancer       Date:  1981-07       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.